Treatment Approach for Skin Lesions Associated with Neuroendocrine Tumors

Diagnostic Evaluation

The National Comprehensive Cancer Network (NCCN) recommends a comprehensive diagnostic workup for skin lesions associated with neuroendocrine tumors, including histopathologic examination with immunohistochemical staining for neuroendocrine markers (synaptophysin, chromogranin A, neuron-specific enolase) 3
Baseline biochemical tests, including chromogranin A and 5-HIAA, should be performed as part of the diagnostic workup 4
Multiphase contrast-enhanced CT or MRI should be used to identify the primary tumor and assess for metastatic disease 2
Somatostatin receptor scintigraphy (Octreoscan) or 68Ga-DOTA-octreotate PET should be used for tumor localization 5, 3

For metastatic disease, treatment should follow the same principles as for metastatic neuroendocrine tumors from other sites, according to the NCCN Guidelines 2
Surgical resection of isolated cutaneous metastases may be considered for symptom control 4
Somatostatin analogs (octreotide, lanreotide) should be used for symptom control in patients with somatostatin receptor-positive tumors 2, 6
Cytotoxic chemotherapy regimens should be based on tumor differentiation, with options including 5-FU, dacarbazine, and epirubicin for well-differentiated tumors, and platinum-based chemotherapy for poorly differentiated tumors 6
Targeted therapies, such as everolimus, may be considered in appropriate cases 7
Tumor-targeted radioactive treatment should be considered for patients with high uptake on somatostatin receptor scintigraphy 5, 6

External beam radiotherapy may provide relief for symptomatic cutaneous lesions 4, 7
Ablative therapies may be considered for limited metastatic disease 6, 7

Patients should be followed at 3-month intervals during treatment with cytotoxic agents or biological therapy 6
Imaging evaluation should be performed at least every 6 months for metastatic disease 5
Biochemical markers, such as chromogranin A, should be monitored every 3-6 months 5, 2